Patient characteristics
| Characteristics at diagnosis . | N (%) . |
|---|---|
| Median age at diagnosis (range), y | 54 (17-74) |
| Sex (M/F), (%) | 450 (57%)/341 (43%) |
| Diagnosis | |
| DLBCL NOS | 540 (68%) |
| HGBCL DH/TH | 32 (4%) |
| HGBCL NOS | 27 (3%) |
| PMLBCL | 55 (7%) |
| Transformed FL | 76 (10%) |
| DLBCL gray zone | 18 (2%) |
| DLBCL T-cell rich | 20 (2%) |
| Other | 8 (1%) |
| Missing | 15 (2%) |
| Ann Arbor stage | |
| I-II | 168 (21%) |
| III-IV | 606 (77%) |
| Missing | 17 (2%) |
| B symptoms | |
| No | 405 (51%) |
| Yes | 354 (45%) |
| Missing | 32 (4%) |
| Bulky disease | |
| No | 504 (64%) |
| Yes | 241 (30%) |
| Missing | 46 (6%) |
| Extranodal involvement | |
| No | 286 (36%) |
| Yes | 464 (59%) |
| Missing | 41 (5%) |
| R-IPI | |
| 0 | 42 (5%) |
| 1-2 | 329 (42%) |
| 3-5 | 346 (44%) |
| Missing | 74 (9%) |
| Response after front line | |
| CR | 443 (56%) |
| PR | 154 (19%) |
| SD | 45 (6%) |
| PD | 149 (19%) |
| Characteristics at diagnosis . | N (%) . |
|---|---|
| Median age at diagnosis (range), y | 54 (17-74) |
| Sex (M/F), (%) | 450 (57%)/341 (43%) |
| Diagnosis | |
| DLBCL NOS | 540 (68%) |
| HGBCL DH/TH | 32 (4%) |
| HGBCL NOS | 27 (3%) |
| PMLBCL | 55 (7%) |
| Transformed FL | 76 (10%) |
| DLBCL gray zone | 18 (2%) |
| DLBCL T-cell rich | 20 (2%) |
| Other | 8 (1%) |
| Missing | 15 (2%) |
| Ann Arbor stage | |
| I-II | 168 (21%) |
| III-IV | 606 (77%) |
| Missing | 17 (2%) |
| B symptoms | |
| No | 405 (51%) |
| Yes | 354 (45%) |
| Missing | 32 (4%) |
| Bulky disease | |
| No | 504 (64%) |
| Yes | 241 (30%) |
| Missing | 46 (6%) |
| Extranodal involvement | |
| No | 286 (36%) |
| Yes | 464 (59%) |
| Missing | 41 (5%) |
| R-IPI | |
| 0 | 42 (5%) |
| 1-2 | 329 (42%) |
| 3-5 | 346 (44%) |
| Missing | 74 (9%) |
| Response after front line | |
| CR | 443 (56%) |
| PR | 154 (19%) |
| SD | 45 (6%) |
| PD | 149 (19%) |
| Characteristics at ASCT . | N (%) . |
|---|---|
| Median age at ASCT (range), y | 56 (18-76) |
| Disease status at salvage therapy | |
| Late relapse | 314 (40%) |
| Early relapse | 128 (16%) |
| Primary refractory | 349 (44%) |
| Second-line therapy | |
| R-ESHAP | 442 (56%) |
| R-DHAP | 48 (6%) |
| R-ICE | 41 (5%) |
| R-GDP | 38 (5%) |
| Other | 195 (25%) |
| Missing | 27 (3%) |
| Conditioning regimen | |
| BEAM | 628 (79%) |
| R-BEAM | 75 (10%) |
| Z-BEAM | 19 (2%) |
| Other | 53 (7%) |
| Missing | 16 (2%) |
| Treatment line at ASCT | |
| Second line | 617 (78%) |
| Third line | 147 (19%) |
| Front line in transformed | 27 (3%) |
| Disease status at ASCT | |
| CR | 481 (61%) |
| PR | 275 (35%) |
| SD | 21 (3%) |
| Not evaluated | 14 (2%) |
| Characteristics at ASCT . | N (%) . |
|---|---|
| Median age at ASCT (range), y | 56 (18-76) |
| Disease status at salvage therapy | |
| Late relapse | 314 (40%) |
| Early relapse | 128 (16%) |
| Primary refractory | 349 (44%) |
| Second-line therapy | |
| R-ESHAP | 442 (56%) |
| R-DHAP | 48 (6%) |
| R-ICE | 41 (5%) |
| R-GDP | 38 (5%) |
| Other | 195 (25%) |
| Missing | 27 (3%) |
| Conditioning regimen | |
| BEAM | 628 (79%) |
| R-BEAM | 75 (10%) |
| Z-BEAM | 19 (2%) |
| Other | 53 (7%) |
| Missing | 16 (2%) |
| Treatment line at ASCT | |
| Second line | 617 (78%) |
| Third line | 147 (19%) |
| Front line in transformed | 27 (3%) |
| Disease status at ASCT | |
| CR | 481 (61%) |
| PR | 275 (35%) |
| SD | 21 (3%) |
| Not evaluated | 14 (2%) |
BEAM, BCNU, etoposide, cytarabine, and melphalan; F, female; HGBCL, high-grade BCL; M, male; PMLBL, primary mediastinal large BCL; R-BEAM, rituximab-BEAM; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-ESHAP, rituximab, etoposide, cytarabine, cisplatin, and methylprednisolone; R-ICE, rituximab, ifosfamide, carboplatin and etoposide; R-GDP, rituximab, gemcitabine, cisplatin, and dexamethasone; TEAM, thiotepa, etoposide, cytarabine, and melphalan; Z-BEAM, yttrium-90-ibritumomab tiuxetan-BEAM.